Because safety validation, regulatory submissions, and clinical deployment constraints make immediate patching unrealistic for many devices. Compensating controls reduce exploitability during the gap between discovery and remediation. They are essential when the organisation must keep the device operational while proving the residual risk is understood and managed.
Why patch timing is different for fielded medical devices
Fielded medical devices are patched under tighter constraints than ordinary IT systems because the patch itself can affect patient safety, clinical workflows, certification status, and vendor supportability. The practical question is not whether to remediate, but how to reduce exposure while preserving safe operation until the device can be validated and deployed in a controlled way.
That makes the remediation window part of the security problem. When a device cannot be patched quickly, teams need temporary safeguards that narrow the attack path, limit exposure, and preserve traceability so the residual risk is explicit rather than assumed away.
What compensating controls do in the interim
compensating control are the controls you use when the preferred fix is delayed or cannot be applied immediately. For medical devices, they should reduce exploitability without changing the device in ways that could disrupt clinical use or violate deployment constraints. Typical measures include segmentation, tightly scoped access paths, logging, removal of unnecessary services, and stronger monitoring around the device boundary.
These controls are not a substitute for remediation. They are a risk-managed bridge, intended to lower the chance that a vulnerable device becomes an easy entry point or a high-impact dependency while the patch is being validated, approved, and scheduled.
When the device participates in identity or access decisions, the same logic applies to compensating controls around access pathways and privileged use. A useful Segregation of Duties (SoD) Guide shows the broader principle: if you cannot remove a risky capability immediately, constrain who can use it, under what conditions, and with what oversight. In healthcare environments, the Healthcare Identity Security Guide is also relevant because devices sit inside clinical workflows, shared environments, and third-party support models where access boundaries matter as much as the device software itself.
How to judge whether the control set is strong enough
The right compensating control set is the one that actually reduces attack surface and blast radius for the specific device, not the one that is easiest to document. If the device is internet-reachable, holds sensitive clinical data, or can affect patient care, the bar is higher than for a low-impact internal asset. Stronger temporary control is warranted when patch delay is long, the vulnerability is actively exploited, or the device has broad network reach.
Use risk-based prioritisation rather than calendar-based comfort. A vulnerability with known active exploitation deserves immediate containment even when patching is delayed, and a device that cannot be safely patched should be isolated until its operational and safety constraints are resolved. For prioritisation, sources such as the CISA Known Exploited Vulnerabilities Catalog and the NIST National Vulnerability Database help teams distinguish a theoretical flaw from one that is already operationally dangerous. The FIRST EPSS can add further prioritisation signal when patch queues are crowded.
Risk and Threat Considerations
Medical devices often fail safely only when their configuration, network context, and update path remain stable. The risk is that a delayed patch leaves a known vulnerability exposed long enough for opportunistic exploitation, lateral movement, or service disruption, while an overaggressive change can create clinical downtime or introduce unsafe behaviour.
Failure mechanism: Attackers or misconfigurations exploit the unpatched device during the validation gap, especially where the device is reachable from shared networks, remote support paths, or overly broad administrative access.
Impact: The result can be device compromise, interruption of care, data exposure, or an unsafe forced tradeoff between security and clinical availability.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
CIS Controls v8 and NIST SP 800-53 Rev 5 set the governance and control requirements practitioners need to meet.
| Framework | Control / Reference | Relevance |
|---|---|---|
| CIS Controls v8 | CIS-4 — Secure Configuration of Enterprise Assets and Software | Medical devices need interim hardening and containment when patching is delayed. |
| CIS-12 — Network Infrastructure Management | Segmentation and restricted pathways are core compensating controls for fielded devices. | |
| Recommendation — Harden device configurations and isolate exposed services until remediation is complete. Segment medical devices and restrict management paths to reduce blast radius. | ||
| NIST SP 800-53 Rev 5 | RA-3 — Risk Assessment | Residual risk must be assessed when patching is delayed and compensating controls are used. |
| SI-2 — Flaw Remediation | Delayed patching and staged remediation are central to the question. | |
| SC-7 — Boundary Protection | Network containment is a primary compensating control for vulnerable fielded devices. | |
| Recommendation — Assess residual device risk before accepting temporary compensating controls. Track flaws, apply fixes when safe, and document interim mitigation steps. Enforce boundary protections around device networks and support channels. | ||
Practitioner Guidance
What to prioritise: Treat compensating controls as a documented interim state with an expiry date, not a permanent workaround. Prioritise the devices with the highest clinical impact, the broadest network reach, and the strongest evidence of active exploitation.
What to verify: Confirm that the control actually changes exposure, for example by limiting reachable management interfaces, isolating the device segment, or reducing privileged paths. If you cannot explain how the control lowers exploitability, it is probably administrative rather than compensating.
Decision rule: If patching cannot be completed safely before the next exposure window, enforce containment first and accept temporary operational friction. If the device must remain in service, ensure the residual risk is explicitly owned, monitored, and approved rather than informally tolerated.
Practitioner takeaway: For fielded medical devices, the goal is not to choose patching or compensating controls as alternatives, but to use compensating controls to keep risk bounded until a safe patch path exists.
Related resources from NHI Mgmt Group
- Who should be accountable for compensating controls on legacy medical devices?
- When should organisations prioritise compensating controls over immediate patching?
- When should organisations use compensating controls instead of immediate separation?
- Who is accountable when compensating controls are used instead of full separation?